Stocks · News reference
HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $50.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 10:42 AM
- Checked
- Jul 15, 2026, 10:42 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32
Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $32.
Read original at benzingaHC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
Read original at benzingaSeaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate
Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(1.78) per share which missed the analyst consensus estimate of $(0.65) by 173.85 percent. This is a 72.19 percent increase over losses of $(6.40) per
Read original at benzinga